---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-091981"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2026-08-06T20:05:41+00:00"
generated_at: "2026-08-06T20:08:59.866223+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MetaVia Q2 net loss $5.3M ($0.90/sh); DA-1726 Phase 1 Part 3 all patients at highest doses; topline data Q4 2026

## Summary
- Net loss of $5.3M ($0.90 per share) for Q2 2026, compared to net loss of $4.0M ($2.87 per share) in Q2 2025.
- Cash and cash equivalents of $12.6M as of June 30, 2026, up from $10.3M at Dec 31, 2025; expects cash to fund operations through 2026.
- All active patients in Phase 1 Part 3 of DA-1726 reached highest planned doses of 48 mg and 64 mg; 16-week topline data expected Q4 2026.
- Presented data at EASL and ADA showing up to 9.1% mean weight loss at 8 weeks on 48 mg dose, with no plateau.
- Planning End-of-Phase 2 meeting with FDA for vanoglipel (DA-1241) in MASH during H2 2026.

## SEC filing metadata
- accession: 0001104659-26-091981
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2026-08-06T20:05:41+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000110465926091981/0001104659-26-091981-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000110465926091981/mtva-20260806x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-091981
- JSON: https://secwatch.observer/filing/0001104659-26-091981.json
- Plain text: https://secwatch.observer/filing/0001104659-26-091981.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.